Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)
NCT00246519Phase 4Completed
- Sponsor
- University of Florida
- Start
- Oct 2005
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hypertension (HTN) comparing Atenolol First with HCTZ First (2 arms). Primary endpoint: Blood Pressure Response at 18 weeks. Started Oct 2005; status: completed.
02
Drugs
atenololhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00246519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246519.